Rhenman & Partners Asset Management AB reduced its stake in shares of The Cigna Group (NYSE:CI – Free Report) by 41.3% during the 4th quarter, HoldingsChannel reports. The fund owned 47,000 shares of the health services provider’s stock after selling 33,000 shares during the period. The Cigna Group accounts for 1.4% of Rhenman & Partners […]
Rhenman & Partners Asset Management AB lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,912 shares of the biopharmaceutical company’s stock after selling 50,088 shares during the quarter. Rhenman & Partners Asset […]
Rhenman & Partners Asset Management AB lowered its stake in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 4.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 220,000 shares of the company’s stock after selling 10,000 shares during the quarter. Axonics […]
Rhenman & Partners Asset Management AB lifted its position in Danaher Co. (NYSE:DHR – Free Report) by 30.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,000 shares of the conglomerate’s stock after acquiring an additional 18,000 shares during the period. […]
Rhenman & Partners Asset Management AB boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 14.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 800,000 shares of the biopharmaceutical company’s stock after acquiring an additional 100,000 […]